Caris Life Sciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Caris Life Sciences, Inc. (NASDAQ:CAI) is a molecular diagnostics company that specializes in precision oncology through advanced AI-driven molecular profiling and sequencing technologies. The company offers comprehensive molecular profiling services, including whole exome sequencing (WES) and whole transcriptome sequencing (WTS) for solid and hematologic tumors; Caris Assure, a pan-cancer blood-based assay utilizing circulating nucleic acid sequencing (cNAS) for therapy selection; MI Cancer Seek, an FDA-approved companion diagnostic for solid tumor profiling in adult and pediatric patients; and liquid biopsy platforms for multi-cancer early detection (MCED), minimal residual disease (MRD) monitoring, and therapy guidance, supported by one of the world's largest clinico-genomic databases exceeding 660,000 patient records. Caris serves oncologists, patients, and biopharma partners across the continuum of cancer care, from early detection and diagnosis to therapy selection and drug development, with applications extending to non-oncology areas such as cardiology and neurology. Founded in 2008 and headquartered in Irving, Texas, the company operates labs and offices in Phoenix, New York, Cambridge, Tokyo, and Basel, providing services in the United States, Europe, Australia, and other international markets. Recent developments include a $168 million growth capital raise in April 2025 led by Braidwell LP with participation from Perceptive Advisors, Woodline, and others, bringing total funding since 2018 to $1.86 billion; the commercial launch of Caris Assure in 2024 following FDA approval of MI Cancer Seek; strategic partnerships such as a January 2024 multimodal data collaboration with Flatiron Health and an April 2024 antibody-drug conjugate alliance with Merck potentially worth up to $1.4 billion in milestones; and the launch of its initial public offering roadshow in June 2025, with shares listed on Nasdaq under CAI.
Capitan Investment Ltd. Announces Adoption of Semi-Annual Reporting
Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
CAI Advances Multicloud and Secure AI Strategy with AWS and Microsoft
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
Caris Life Sciences Reports First Quarter 2026 Financial Results
Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis
Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies
Capitan Investment Ltd. Announces Appointment of Chief Financial Officer and Chair
Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference
Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center
Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
Caris Life Sciences: Post-IPO Pullback Creates A Long-Term Buy Opportunity